CHEMBIO DIAGNOSTICS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-28: Form 8-K; Period of report 2021-12-21; Description 8.01 Other Events; Details 8.01.
- 2021-12-08: Form 8-K; Period of report 2021-12-01; Description 8.01 Other Events; Details 8.01.
- 2021-12-06: Form 8-K; Period of report 2021-11-30; Description 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 1.01.
- 2021-11-22: Form 8-K; Period of report 2021-11-22; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-28 | 8-K | 2021-12-21 | 8.01 Other Events | 8.01 On December 21, 2021, the U.S. Food and Drug Administration, or FDA, notified us that it was declining to review our application for an emergency use authorization, or EUA, for the DPP Respiratory Antigen Panel. | brhc10032317_8k.htm |
| 2021-12-08 | 8-K | 2021-12-01 | 8.01 Other Events | 8.01 On December 1, 2021, we received notice from the U.S. Food and Drug Administration, or FDA, that the FDA would require additional data related to our Clinical Laboratory Improvement Amendment, or CLIA, waiver submission for the DPP HIV-Syphilis test system. | brhc10031603_8k.htm |
| 2021-12-06 | 8-K | 2021-11-30 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On November 30, 2021, we entered into an amendment of our existing employment agreement with Javan Esfandiari, our Executive Vice President and Chief Science and Technology Officer. | brhc10031550_8k.htm |
| 2021-11-22 | 8-K | 2021-11-22 | 8.01 Other Events | 8.01 On November 22, 2021, we issued a press release titled “Chembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) Ltd.” A copy of the press release is included as Exhibit 99.1 to this report. | brhc10031042_8k.htm |
| 2021-11-15 | 8-K | 2021-11-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On October 18, 2021, we filed a Current Report on Form 8-K with the Securities and Exchange Commission disclosing that Neil A. Goldman, our Executive Vice President and Chief Financial Officer, had notified us that he would be terminating his employment with our company. 8.01 On July 20, 2021, we received a $28.3 million purchase order from Bio-Manguinhos, or the Bio-Manguinhos Purchase Order, for the purchase of DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the needs of Brazil’s Ministry of Health in addressing the COVID-19 pandemic. | brhc10030841_8k.htm |
| 2021-11-04 | 8-K | 2021-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2021, we issued a press release announcing financial results for the quarter ended September 30, 2021. | brhc10030390_8k.htm |
| 2021-10-18 | 8-K | 2021-10-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 16, 2021, Neil A. Goldman, our Executive Vice President and Chief Financial Officer, notified us that he would be terminating his employment with our company, effective on or about November 5, 2021, in order to pursue another opportunity. | brhc10029900_8k.htm |
| 2021-08-05 | 8-K | 2021-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2021, we issued a press release announcing financial results for the quarter ended June 30, 2021. | brhc10027666_8k.htm |
| 2021-07-22 | 8-K | 2021-07-22 | 8.01 Other Events | 8.01 On July 22, 2021, we issued a press release titled “Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund.” A copy of the press release is included as Exhibit 99.1 to this report. | brhc10027141_8k.htm |
| 2021-07-21 | 8-K | 2021-07-20 | 8.01 Other Events | 8.01 On July 20, 2021, we issued a press release titled “Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil.” A copy of the press release is included as Exhibit 99.1 to this report. | brhc10027112_8k.htm |
| 2021-07-19 | 8-K | 2021-07-19 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.02 We set forth below our preliminary estimates of certain operating results for the second quarter of 2021, including our cash and cash-equivalents position at June 30, 2021, together with information relating to our limited cash position. 8.01 The following discussion updates, and should be read in conjunction with, the description of our business and other information set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as amended, and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, each as filed with the SEC. | brhc10026983_8k.htm |
| 2021-06-25 | 8-K | 2021-06-25 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 We held our 2021 Annual Meeting of Stockholders on June 25, 2021. | brhc10026262_8k.htm |
| 2021-06-10 | 8-K | 2021-06-10 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 Since September 2018 the terms of our bylaws have provided that the bylaws could be amended only by action of the board of directors. | brhc10025685_8k.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2021, we issued a press release announcing financial results for the quarter ended March 31, 2021. | brhc10024227_8k.htm |
| 2021-03-11 | 8-K | 2021-03-11 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2021, we issued a press release announcing financial results for the quarter and fiscal year ended December 31, 2020. | brhc10021624_8k.htm |
| 2021-03-08 | 8-K | 2021-03-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 4, 2021, our board of directors elected David Bespalko as a member of the board, effective immediately and continuing until our 2021 annual meeting of stockholders. | brhc10021418_8k.htm |